Aligos Therapeutics Inc (ALGS)
0.72
-0.07
(-8.57%)
USD |
NASDAQ |
May 10, 16:00
0.72
0.00 (0.00%)
After-Hours: 20:00
Aligos Therapeutics Enterprise Value: -76.12M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | -76.12M |
| May 08, 2024 | -76.44M |
| May 07, 2024 | -75.93M |
| May 06, 2024 | -74.41M |
| May 03, 2024 | -74.40M |
| May 02, 2024 | -71.69M |
| May 01, 2024 | -77.44M |
| April 30, 2024 | -77.82M |
| April 29, 2024 | -80.18M |
| April 26, 2024 | -76.53M |
| April 25, 2024 | -73.81M |
| April 24, 2024 | -72.97M |
| April 23, 2024 | -73.38M |
| April 22, 2024 | -75.09M |
| April 19, 2024 | -78.95M |
| April 18, 2024 | -75.69M |
| April 17, 2024 | -76.15M |
| April 16, 2024 | -72.52M |
| April 15, 2024 | -68.00M |
| April 12, 2024 | -60.04M |
| April 11, 2024 | -55.50M |
| April 10, 2024 | -57.01M |
| April 09, 2024 | -55.50M |
| April 08, 2024 | -54.74M |
| April 05, 2024 | -57.01M |
| Date | Value |
|---|---|
| April 04, 2024 | -62.12M |
| April 03, 2024 | -59.28M |
| April 02, 2024 | -61.70M |
| April 01, 2024 | -63.71M |
| March 28, 2024 | -61.55M |
| March 27, 2024 | -61.62M |
| March 26, 2024 | -58.52M |
| March 25, 2024 | -64.67M |
| March 22, 2024 | -60.79M |
| March 21, 2024 | -63.82M |
| March 20, 2024 | -63.59M |
| March 19, 2024 | -65.21M |
| March 18, 2024 | -66.09M |
| March 15, 2024 | -65.98M |
| March 14, 2024 | -69.90M |
| March 13, 2024 | -69.87M |
| March 12, 2024 | -69.87M |
| March 11, 2024 | -69.12M |
| March 08, 2024 | -72.13M |
| March 07, 2024 | -65.86M |
| March 06, 2024 | -62.11M |
| March 05, 2024 | -60.62M |
| March 04, 2024 | -61.35M |
| March 01, 2024 | -50.84M |
| February 29, 2024 | -61.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-138.82M
Minimum
May 06 2022
1.178B
Maximum
Dec 23 2020
155.60M
Average
-52.77M
Median
Jul 27 2023
Enterprise Value Benchmarks
| Mirum Pharmaceuticals Inc | 1.224B |
| CEL-SCI Corp | 78.27M |
| AIM ImmunoTech Inc | 9.406M |
| IGC Pharma Inc | 31.90M |
| NovaBay Pharmaceuticals Inc | 2.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.89M |
| Revenue (Quarterly) | 2.681M |
| Total Expenses (Quarterly) | 28.68M |
| EPS Diluted (Quarterly) | -0.3714 |
| Profit Margin (Quarterly) | -1.04K% |
| Earnings Yield | -241.9% |
| Normalized Earnings Yield | -241.86 |